Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BridgeBio Pharma, Inc.BBIO · Entity 3360 | Chief Accounting Officer | August 16, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BridgeBio Pharma, Inc.
Report date August 16, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 122,687 |
Reported balance
After 2026-08-16 transaction · row 1
1 source rowRow 1 · 2026-08-16 · Tax withholding · Disposed 4,714 · Balance 122,687 F1: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 9,262 shares of Common Stock underlying the Reporting Person's RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 9,262 shares of Common Stock underlying the Reporting Person's RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 16, 2026 Filed Aug 18, 2026 22:02 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 4,714 | $79.86 | $376,460.04 |
DisclosureSEC source: 0001470831-26-000835 · wk-form4_1787090542.xml · nonDerivative · entry 1 Apuli Maricel · CIK 0002058197 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,687 F1 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 9,262 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| July 30, 2026 Filed Aug 3, 2026 20:20 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 2,000 | $80.06 | $160,120.00 |
DisclosureSEC source: 0001470831-26-000745 · wk-form4_1785788451.xml · nonDerivative · entry 1 Apuli Maricel · CIK 0002058197 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 127,401 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on September 8, 2025. Read SEC document |
| May 16, 2026 Filed May 19, 2026 20:26 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 4,714 | $66.13 | $311,736.82 |
DisclosureSEC source: 0001470831-26-000471 · wk-form4_1779222400.xml · nonDerivative · entry 1 Apuli Maricel · CIK 0002058197 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,401 F1 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 9,260 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| April 30, 2026 Filed May 4, 2026 20:22 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 2,000 | $71.58 | $143,160.00 |
DisclosureSEC source: 0001470831-26-000410 · wk-form4_1777926142.xml · nonDerivative · entry 1 Apuli Maricel · CIK 0002058197 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,115 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on September 8, 2025. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 20:32 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantCommon Stock | 14,170 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000302 · wk-form4_1774038735.xml · nonDerivative · entry 1 Apuli Maricel · CIK 0002058197 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,115 F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs shall vest with respect to 1/16th of the underlying shares on May 16, 2026, and as to 1/16th of the underlying shares each quarter thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:11 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 2,000 | $66.00 | $132,000.00 |
DisclosureSEC source: 0001470831-26-000225 · wk-form4_1772226672.xml · nonDerivative · entry 1 Apuli Maricel · CIK 0002058197 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,945 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on September 8, 2025. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 23:39 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 510 | $74.31 | $37,898.10 |
DisclosureSEC source: 0001470831-26-000186 · wk-form4_1771457961.xml · nonDerivative · entry 2 Apuli Maricel · CIK 0002058197 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,945 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on September 8, 2025. Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 23:39 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 4,349 | $75.25 | $327,262.25 |
DisclosureSEC source: 0001470831-26-000186 · wk-form4_1771457961.xml · nonDerivative · entry 1 Apuli Maricel · CIK 0002058197 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,455 F1 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 8,377 shares of Common Stock underlying the Reporting Person's RSUs. F2 · balance_after: Includes 510 shares of the Issuer's Common Stock acquired by the Reporting Person on February 13, 2026 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 23:24 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 2,003 | $75.15 | $150,525.45 |
DisclosureSEC source: 0001470831-25-000418 · wk-form4_1765927454.xml · nonDerivative · entry 1 Apuli Maricel · CIK 0002058197 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,294 F1 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 3,944 shares of Common Stock underlying the Reporting Person's Restricted Stock Units. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 12:53 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 2,000 | $74.26 | $148,520.00 |
DisclosureSEC source: 0001470831-25-000392 · wk-form4_1765371229.xml · nonDerivative · entry 1 Apuli Maricel · CIK 0002058197 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,297 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on September 8, 2025. Read SEC document |
| November 16, 2025 Filed Nov 19, 2025 00:23 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 4,781 | $66.39 | $317,410.59 |
DisclosureSEC source: 0001470831-25-000349 · wk-form4_1763511805.xml · nonDerivative · entry 1 Apuli Maricel · CIK 0002058197 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,297 F1 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 9,410 shares of Common Stock underlying the Reporting Person's Restricted Stock Units. Read SEC document |
| August 16, 2025 Filed Aug 19, 2025 23:40 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 4,781 | $51.32 | $245,360.92 |
DisclosureSEC source: 0000950170-25-110276 · ownership.xml · nonDerivative · entry 1 Apuli Maricel · CIK 0002058197 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,078 F1 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 9,409 shares of Common Stock underlying the Reporting Person's Restricted Stock Units. Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 22:29 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 1,000 | $45.44 | $45,440.00 |
DisclosureSEC source: 0000950170-25-106751 · ownership.xml · nonDerivative · entry 1 Apuli Maricel · CIK 0002058197 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,859 Read SEC document |
| May 16, 2025 Filed May 20, 2025 21:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 4,780 | $33.84 | $161,755.20 |
DisclosureSEC source: 0000950170-25-075340 · ownership.xml · nonDerivative · entry 1 Apuli Maricel · CIK 0002058197 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,859 F1 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 9,408 shares of Common Stock underlying the Reporting Person's Restricted Stock Units. Read SEC document |
| May 02, 2025 Filed May 6, 2025 20:45 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 1,026 | $38.51 | $39,509.11 |
DisclosureSEC source: 0000950170-25-064567 · ownership.xml · nonDerivative · entry 1 Apuli Maricel · CIK 0002058197 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,639 Read SEC document |
| March 19, 2025 Filed Mar 21, 2025 22:03 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantCommon Stock | 23,660 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-043376 · ownership.xml · nonDerivative · entry 1 Apuli Maricel · CIK 0002058197 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,665 F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs shall vest with respect to 1/16th of the underlying shares on May 16, 2025, and as to 1/16th of the underlying shares each quarter thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.